Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine

BMC Complementary and Alternative Medicine

Research Article

Aili Xu¹  Xu Wei²  Yanming Xie³  Hao Shen³ 

[1] Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, 100102, Beijing, China;Department of Scientific Research, Wangjing Hospital, China Academy of Chinese Medical Sciences, 100102, Beijing, China;Institute of Orthopaedics of Beijing Integrative Medicine, 100700, Beijing, China;Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, 100700, Beijing, China;

关键词: Qianggu Capsule;    Primary osteoporosis;    Chinese patent medicine;    Systematic review;   

DOI  :  10.1186/s12906-017-1617-3

 received in 2016-02-16, accepted in 2017-02-02,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundQianggu Capsule, a Chinese patent medicine, has been widely applied in the clinical practice of primary osteoporosis (POP) in recent years. This study aims to summarize the effectiveness and safety of Qianggu Capsule in treating POP.MethodsWe searched seven electronic databases, all searches ended in 30 September, 2015. All randomised controlled trials comparing the efficacy of Qianggu Capsule treatment with no treatment, placebo or conventional therapy for POP were included. Combined therapies of Qianggu Capsule were also included. Cochrane risk of bias tool was used to assess methodological quality of primary studies. Revman 5.2.0 software was used for data analysis.ResultsTen trials were enrolled. The combined effect showed that Qianggu Capsule plus Caltrate D was better than Caltrate D on lumbar spine bone mineral density (BMD) (MD = 0.05 g/cm2; 95% CI: 0.02–0.07; P = 0.0004), femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.001), femoral great trochanter BMD (MD = 0.04 g/cm2; 95% CI: 0.03–0.06; P < 0.001). Meta-analysis exhibited a significant antiosteoporosis effect of Qianggu Capsule on femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.003) and femoral trochanteric BMD (MD = 0.07 g/cm2; 95% CI: 0.02–0.12; P = 0.006) compared with α-D3 capsule. However, the methodological quality of included studies was low. Constipation and dry mouth were the most common adverse drug reactions of Qianggu Capsule. Finally the evidence level was evaluated to be low or very low.ConclusionsThe effect of Qianggu Capsule for POP was supported in improving BMD. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research.

【 授权许可】

CC BY   
© The Author(s). 2017